Peptide Therapeutics Market Size, Share, Growth Analysis, By Application(Cancer, Metabolic, Cardiovascular Disorder, Respiratory), By Type of Manufacturers(In-house, Outsourced), By Type(Generic, Innovative), By Route of Administration(Parenteral, Oral, Pulmonary, Mucosal), By Synthesis Technology(Solid Phase Peptide Synthesis (SPPS), Liquid Phase Peptide Synthesis (LPPS), Hybrid Technology), By Region - Industry Forecast 2024-2031

Peptide Therapeutics Market size was valued at USD 40.69 billion in 2019 and is poised to grow from USD 43.11 billion in 2023 to USD 68.4 billion by 2031, growing at a CAGR of 5.94% in the forecast period (2024-2031).

Growing prevalence of chronic diseases around the world and increasing investments in drug discovery and development are projected to drive peptide therapeutics demand in the future. Rising awareness regarding the low toxicity of peptide therapeutics among patients and medical professionals will also benefit peptide therapeutics market growth in the future. Advancements in peptide synthesis are also expected to play a crucial role in governing sales of peptide therapeutics over the coming years. High adoption of targeted therapies for the treatment of several indications owing to their high specificity in treatment will also favor the demand for peptide therapeutics. Surging incidence of cancer is also expected to benefit the market growth as use of peptide therapeutics in treatment of cancer picks up pace. Supportive government funding to advance biopharmaceutical research will also create new opportunities for peptide therapeutics companies. However, limited oral bioavailability, high costs of production, and competition from biologics and other drugs are estimated to be key restraints for market growth in the long run. 

US Peptide Therapeutics Market is poised to grow at a sustainable CAGR for the next forecast year.